The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage biotech's stock took an almost 6% hit on Thursday, following some dispiriting ...
Some results have been hidden because they may be inaccessible to you